Literature DB >> 19265089

The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension.

Harm J Bogaard1, Kohtaro Abe2, Anton Vonk Noordegraaf1, Norbert F Voelkel3.   

Abstract

Pulmonary arterial hypertension (PAH) is a deadly disease in which vasoconstriction and vascular remodeling both lead to a progressive increase in pulmonary vascular resistance. The response of the right ventricle (RV) to the increased afterload is an important determinant of patient outcome. Little is known about the cellular and molecular mechanisms that underlie the transition from compensated hypertrophy to dilatation and failure that occurs during the course of the disease. Moreover, little is known about the direct effects of current PAH treatments on the heart. Although the increase in afterload is the first trigger for RV adaptation in PAH, neurohormonal signaling, oxidative stress, inflammation, ischemia, and cell death may contribute to the development of RV dilatation and failure. Here we review cellular signaling cascades and gene expression patterns in the heart that follow pressure overload. Most data are derived from research on the left ventricle, but where possible specific information on the RV response to pressure overload is provided. This overview identifies the gaps in our understanding of RV failure and attempts to fill them, when possible. Together with the online supplement, it provides a starting point for new research and aims to encourage the pulmonary hypertension research community to direct some of their attention to the RV, in parallel to their focus on the pulmonary vasculature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265089     DOI: 10.1378/chest.08-0492

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  224 in total

Review 1.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 2.  Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Authors:  Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

Review 3.  Imaging the right ventricle--current state of the art.

Authors:  Luc L Mertens; Mark K Friedberg
Journal:  Nat Rev Cardiol       Date:  2010-08-10       Impact factor: 32.419

4.  Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension.

Authors:  Jens Vogel-Claussen; Jan Skrok; Monda L Shehata; Sukhminder Singh; Christopher T Sibley; Danielle M Boyce; Noah Lechtzin; Reda E Girgis; Steven C Mathai; Thomas A Goldstein; Jie Zheng; João A C Lima; David A Bluemke; Paul M Hassoun
Journal:  Radiology       Date:  2010-10-22       Impact factor: 11.105

Review 5.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

6.  Right ventricular protein expression profile in end-stage heart failure.

Authors:  Yan Ru Su; Manuel Chiusa; Evan Brittain; Anna R Hemnes; Tarek S Absi; Chee Chew Lim; Thomas G Di Salvo
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

7.  Increased TMEM16A-encoded calcium-activated chloride channel activity is associated with pulmonary hypertension.

Authors:  Abigail S Forrest; Talia C Joyce; Marissa L Huebner; Ramon J Ayon; Michael Wiwchar; John Joyce; Natalie Freitas; Alison J Davis; Linda Ye; Dayue D Duan; Cherie A Singer; Maria L Valencik; Iain A Greenwood; Normand Leblanc
Journal:  Am J Physiol Cell Physiol       Date:  2012-10-03       Impact factor: 4.249

8.  Skeletal muscle mitochondrial dysfunction precedes right ventricular impairment in experimental pulmonary hypertension.

Authors:  Irina Enache; Anne-Laure Charles; Jamal Bouitbir; Fabrice Favret; Joffrey Zoll; Daniel Metzger; Monique Oswald-Mammosser; Bernard Geny; Anne Charloux
Journal:  Mol Cell Biochem       Date:  2012-10-26       Impact factor: 3.396

9.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

10.  Impact of the Right Ventricular Sokolow-Lyon Index in Children with Idiopathic Pulmonary Arterial Hypertension.

Authors:  Johannes Krämer; Felix Kreuzer; Michael Kaestner; Peter Bride; Fabian von Scheidt; Jannos Siaplaouras; Heiner Latus; Dietmar Schranz; Christian Apitz
Journal:  Pediatr Cardiol       Date:  2018-03-14       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.